Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance and pharmacokinetics study of oral [14C]-SAR443820 in healthy adult men
NL-OMON59367Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oditrasertib in amyotrophic lateral sclerosis (ALS), sponsored by Sanofi. Primary endpoints: Pharmacokinetics, Excretion balance and 1 more. Started Jun 2023; status: completed.
02
Drugs
oditrasertib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON59367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59367.